EPIDEMIOLOGY OF PERTUSSIS IN JAPAN
Prevalence of pertussis has been surveyed by two different ways, one being the obligation of case notification by physicians on the legal basis of Infectious Disease Prevention Law and the other being the field surveillance studies conducted voluntarily as a special epidemiological project.
The physicians who found cases to be diagnosed as pertussis by their medical examination are obliged to report the incidence to the Ministry of Health and Welfare through the local health authorities. The Statistics and Information Department of the Minister's Secretariat compiles the reports from the whole country and issues the monthly report of pertussis and other notifiable infectious diseases. Table I shows the summary of notifications during the period from 1947 to 1979. The figures in the table should be taken as an indicator of the general trend of pertussis prevalence, because such notifications have been made by a limited number of fixed co-operative physicians in each prefecture . In this regard, the statistics are those of a kind of sampling study rather than inclusive data. It is generally stated that the actual number of cases may be ten times as many as the notifications.
1947-1950
Nevertheless, Table I must be a material showing the basic pattern of pertussis epidemiology in this country. The notification number decreased with the rise-and -fall tendency of four year intervals. During the period from 1947 to 1950, pertussis was spread widely in the crowded communities. The reconstruction of Japan, which was completely destructed during World War II, was still at its beginning. Housing and environmental sanitation were in the poorest condition. The birth rate and child population rose sharply. The incidence of pertussis was of the level higher than 100 per 100,000 in this period. It must be noted that the incidence level as such was higher than those of bacillary dysentery and typhoid fever in the same period. due to pertussis since 1951 probably because of the appearance of effective antibiotics to control secondary infection. The declining curve of incidence ran down to the lowest level of 200 to 400 in the period from 1971 to 1974. During twenty-five years upto this time, the socio-economical condition was greatly improved, and pertussis vaccine was changed into diphtheria-pertussis combined vaccine (DP) and further into diphtheria-pertussis-tetanus combined vaccine (DPT) accompanied with the improved quality of each component. Figure 1 shows age distribution of pertussis cases in 1963, 1964 and 1973 . The age group of 0 year had the highest incidence rate in 1963 and 1964 and around 80% of the notifications were of children under six years' old. Figure 2 shows the seasonal changes of pertussis incidence in three separate years. The notification rate is usually the highest in July or in August. This is rather peculiar in view of the fact that infections of the upper respiratory tract are frequent usually in the winter. History o f pertussis vaccination in bacteriologically confirmed patients (Kimura, 1976) concern to the untoward reactions to small pox vaccine. Though arguments in mass communication were not always balanced, it is not denied that they made a turning point of the vaccination policy in Japan. In Okayama Prefecture, DPT vaccination has been refused by physicians since April, 1973 on the experience of an unhappy vaccination accident. This vaccination boycott soon resulted in the pertussis epidemic starting from the autumn of 1974. The epidemic was followed by the surveillance system organized within the prefecture. The surveillance detected 72 patients in 1975 and totally 300 including those in the surrounding prefectures. Not a few of them under one year had rather severe clinical symptoms (Kitamura et al., 1976) . Age and month distributions of incidences were not different from the reported features of the previous epidemics. In 1977, this prefecture was still a pertussis-prevalent area in Japan. Such return of pertussis became evident in the whole country year after year since 1975 as judged from the notification number (Table I) (Fig. 3) . It is almost certain that the total notification would be more than 10,000 at the end of 1979. Thus, this epidemiological situation of pertussis will be of the same level as that of 20 years ago. Table III shows the age distribution of pertussis cases in 1977. It is known from this table that more than two-third of the total cases were in the individuals under 2 years' old. Mizuhara (1979) reported that more than 90% of the recent cases were among those who had not been vaccinated. Table IV shows age distribution of pertussis deaths of babies in 1977 according to the national vital statistics. The table presents a convincing evidence to prove that pertussis is still a fatal disease of babies when attacked within a few months after birth. In Japan, a surveillance system for some specified infectious diseases was established in 1962 as a joint project between the Ministry of Health and Welfare and the public health bureaus of co-operator prefectural governments. The main purpose of this project was to see the nation-wide situation of the antibody level through the field study conducted in one or two communities sampled in each prefecture, namely the survey of community immunity against infectious diseases. On the basis of collected data and information, the National Government is expected to foresee the possible future epidemic and to establish the policy to control them including vaccination program. Laboratory work is conducted by prefectural hygiene laboratories and NIH. The statistics are done by the Communicable Disease Surveillance Division of the Ministry of Health and Welfare and National Serum Reference Bank placed in NIH. The infectious diseases under this surveillance have long been polio, diphtheria, influenza, Japanese encephalitis and rubella. Since 1976, however, pertussis has been added to the above list in order to cope with the recent pertussis vaccine problems.
Fifteen prefectures including Tokyo-to and Osaka-fu joined this project. One area was selected from each prefecture as the place for survey, and 200 individuals were sampled there as the objects of serological examinations. They consisted of four age groups of equal 50; 0 to 2, 3 to 5, 6 to 10 and 11 to 14 years' old, respectively. Blood samples were collected from them and subjected to the examination for serum agglutinin levels against two kinds of antigen , one being the organisms of the vaccine strain (Tohama-Maeno , serotype 1, 2) and the other those of the wild strain (Yamaguchi-Kobayashi , serotype 1, 3). These antigens and the standard antiserum were supplied by NIH . Statistical treatment was made separately concerning the group of notified patients and the group of apparently healthy individuals.
The data upto 1977 have already been reported. Figure 4 shows age distribution curves of antibody positive rates to the vaccine strain in healthy indi- 
PREVENTIVE VACCINATION LAW
In Japan, only small pox vaccination has long been carried out as the compulsory one by the law enacted in 1909. Some other kinds of vaccination were also conducted, but only optionally and as mass vaccination in the army. When World War II came to the end in 1945, many infectious diseases including those imported by repatriation became prevalent in the whole country. The poorest condition in nutrition, housing and environmental sanitation accelerated the epidemics. In view of such situation, Occupation Forces issued a memo- randum soon after landing to Japanese Government for the improvement of public health condition. Preventive vaccination was regarded by them as one of the main plans to cope with the nation-wide epidemics at that time. In addition, they advised the establishment of a national institute responsible for the quality control of vaccines. On June 30, 1948, Preventive Vaccination Law was formulated, in which 12 infectious diseases were specified as the objects of vaccination. The law has been revised several times since that time. It appears that pertussis vaccination has been continuously the most important one in the national policy of vaccination, and it is now the only one using killed bacterial vaccine for the regular vaccination on the legal basis. NIH was founded on May 22, 1947 as the national biologics control laboratory.
In accordance with the changes in epidemiological situation, the improve- ment of vaccine quality and the relatively increased weight of untoward reactions in public recognition, the regulations for vaccination practice have also been revised from time to time reflecting the recommendations of the Committee for Preventive Vaccination. As for pertussis vaccine, it has changed from the single vaccine to the combined types (DP and DPT vaccines). The background research activities which make these changes possible will be described in a later chapter. The history above is summarized briefly in Table V (Table I ) and also by serum epidemiology as described in previous chapters.
In Japan, the regular mass vaccination in communities must be made under instructions of the director of the regional health center on the day specified by the headman of the village or the town. Physicians in contract with the village (town) headman are to engage in medical preexamination and vaccine injection.
QUALITY CONTROL OF PERTUSSIS VACCINE
Pharmaceutical Affairs Law: The quality control and standadization of vaccines used for the regular vaccination are carried out on the legal basis of Pharmaceutical Affairs Law formulated in 1948 and revised and rearranged in 1960. The law defines that the specified drugs for medical use must be subjected to national control tests made by the organization specified by Minister of Health and Welfare. As far as biologics (vaccines and blood products) and antibiotics are concerned, the responsible organization is NIH. The Law also states that Minister of Health and Welfare can formulate regulations necessary for the national control test in consultation with the National Council of Pharmacy. The legal system stated above was introduced soon after the end of World War II, probably on the suggestions from the Occupation Forces.
Minimum Requirements for Biological Products: The regulations for the quality control of biologics are called Minimum Requirements for Biological Products and they have been playing an important role of guidance for vaccine production and control tests. No vaccine is used unless it passes the national control tests to examine whether it conforms to the minimum requirements. The control tests consist of chemical and biological tests to confirm the safety and potency of vaccines. The requirements show the methods of vaccine assay and the minimum pass level of each vaccine.
The 
body-weight gain at the end of 7 days, and (3) late mortality. Their analytical and comparative study with separated bacterial components demonstrated that the first check point is concerned with endotoxin and heat-labile toxin and the second and third check points are associated with lymphocytosis-promoting factor (LPF). In this regard, the mouse weight-gain test will be interpreted as a single test for three toxic components. In addition, they made extensive basic research concerning the problems associated with the test method for the toxic components of pertussis bacilli. For example, they found that endotoxin affects not only the total leukocyte count but also the leukocyte proportions (Kurokawa, 1974) , and recommended that the test for LPF should be made with two reference preparations, a standard vaccine and LPF preparation containing little endotoxin, and with appropriate statistical treatment of the data (Kurokawa, 1978) . Other research experiences of them also contributed greatly to Minimum Requirements for Pertussis Vaccine.
The Status of National Control Test of Pertussis Vaccine: Table VII shows the status of the national control tests of pertussis vaccine during the period from 1963 to 1978. It is rather surprising to see that many lots of the vaccine failed the assay in the earlier part of this period because of the unsatisfactory results in safety or potency tests or both. However, since 1963, the vaccine quality was much improved as known from the decreased number of failed vaccine. The strict requirement for the higher protective potency (no less than 7.2 I.U. per single human dose) may have been responsible for the above status of vaccine assay.
Production o f Pertussis Vaccine: In Japan, almost all vaccines including pertussis vaccine have been produced and provided mostly by private and prefectural enterprises, only one exception being pest vaccine which is produced by the Government institute (NIH). The production is regulated by Pharmaceutical Affairs Law and the related Government decrees. As far as vaccines are concerned, it is requested that the whole manufacturing processes are completed in a single factory under self control tests for each of the processing steps (single harvest, final bulk and final lot). This principle was established in 1968 by adopting WHO recommendations. The control test for each step is shown in Table VI . Though the whole manufacturing processes follow the written manual to fulfil the minimum requirements, it appears that there are still many undefined conditions which influence the quality of vaccine products. There are some accumulated evidences to indicate that a delicate relationship exists between culture medium conditions and the properties of produced vaccine, and that slight changes in the growth conditions may reduce or increase the toxicity of pertussis vaccine. Therefore, the empirical knowledge of long years may be profitable for the production of less toxic and more potent vaccines. At the present time, there are 10 vaccine makers in Japan, and seven of them produce DPT vaccine. The amount of test-passed pertussis vaccine in each year is shown in Fig. 8 . Fig. 8 . Annual change in the production of pertussis and combined (DP and DPT) vaccines.
THE RESEARCH COMMITTEE ACTIVITIES FOR THE IMPROVEMENT OF PERTUSSIS VACCINE AND VACCINATION METHOD
As already described, the quality of pertussis vaccine has been improved for the past 30 years, and the vaccination procedure has been changed in accordance with this improvement. It must be stated here that these changes have been made possible by the research committee activities supported by Government and private funds. At least, four research groups were organized in the earlier period (1951 to 1957) to study the protective effect of pertussis vaccine and its untoward reactions and to improve the vaccine quality. These (Tables  VIII,  IX) .
TABLE VIII
Percent distribution of antibody levels to pertussis bacilli 4 weeks after primary 3 injections of DPT, each with 0.5 ml, in three different injection schedules (Mizuhara, 1973) In the long-term activity of the Combined Vaccine Research Committee , the elevation of body temperature was taken as an indicator of vaccine toxicity . Meanwhile, the committee members have not encountered any serious untoward reaction such as encephalopathy. Probably, the population size of children employed for their field and clinical studies may not have been large enough to experienec the very rare incidence of encephalopathy (Someya et al ., 1979b) . Besides, it is true that physicians in general have been so reluctant , from one reason to another, in notifying such serious accidents of their own experience . Because of these state of affairs, vaccination accidents have long been a problem of limited publicity in Japan. However , this situation changed suddenly in 1970, when the fatal case and encephalopathy due to small pox vaccination became widely known as a social problem through mass communication .
The literatures from the western countries of severe neurotoxic reactions to pertussis vaccine have been known among a limited number of Japanese physicians who have particular concerns with the vaccination. They include those of Madsen (1933) , Byers and Moll (1948) , Strom (1960 Strom ( , 1967 and so on.
In Japan, Arima et al. (1956) reported five cases of encephalopathy occurring in conjunction with pertussis vaccination. All the cases were male . The characteristics of this encephalopathy were its early occurrence after injection , mostly within 24 hr, a relatively short duration of fever, convulsion of various grades , and the succeeding disturbance of consciousness. They added that most of these five cases had anamnesis of convulsion or allergic diseases before vaccination . In three cases, encephalopathy occurred after the first injection . In the remaining two, it occurred after the 2nd and 3rd injection, respectively . Ito et al. (1966) experienced a fatal case of a one-year female baby occurring within 5 hr after injection of DP vaccine. At autopsy, enlargement of the thymus and inflammation of the spleen and lymphnodes were acknowledged . According to the information of the Ministry of Health and Welfare, there was another fatal case with convulsion occurring 14 hr after the 3rd injection of DP vaccine in 1962, and there were also three cases of dyspnea and convulsion in a DPvaccinated group of 55 individuals in 1964 (Komatsushiro , 1966) .
In keeping with the increasing publicity of encephalopathy associated with small pox vaccination since the spring of 1970, accidents probably due to DPT vaccine have also been reported from time to time. The surveillance conducted by the research committee headed by S. Okinaka on post-vaccination neurological disturbances found 10 cases of DPT-associated encephalopathy . Shirai et al. (1971) reported five cases of severe neurotoxic reactions experienced in their own clinic for 2 years. Four of them had convulsion, sometimes recurrently, as the main complaint, and the remaining one showed temporary loss of consciousness with high fever.
Quite recently, Kurokawa (1979) if not so frequent, are a serious obstacle to satisfactory performance of the national program of pertussis vaccination. The best way to overcome this problem is to develop a new component vaccine made of purest possible preventive antigen. However, the relation between protectivity and toxicity is still a matter of research and discussion. In fact, pertussis bacilli have many biologically active substances or toxic components. Therefore, this species of bacteria has long been a subject of active investigation both from the academic and practical viewpoints. Such biologically active substances ever reported are heat-labile skin-necrotizing toxin, endotoxin, K-agglutinogen, histaminesensitizing factor, LPF, hemagglutinin (HA), protective antigen, islet-activating protein, and some others. However, there is presently no evidence to prove that anyone of them is responsible for the induction of neurotoxic reactions in humans. A practically important point is whether the protective antigen is a single entity independent of other toxic components stated above or it is associated with any of them. To solve this problem, a lot of work has been done in this country. However, it is not within the scope of this review to make an 
SUMMARY
The experience in Japan that pertussis was controlled by the nation-wide regular vaccination and that the reincrease of case notification occurred recently after the decrease of vaccine acceptance rate upholds the view that pertussis vaccine produced under the national control system is fully protective.
Though the recent decrease of the vaccine acceptance rate was due to the public reaction to rather inbalanced arguments concerning the vaccine risk, it is also true that a more potent and less toxic component vaccine is urgently needed at this moment. KOMATSUSHIRO, E. (1966) The test sample shall be injected intraperitoneally into at least five mice of about 5 weeks of age at a dose of 0.3 ml. The inoculated animals shall be observed for 7 days. The mean body weight 3 days after injection shall be no less than that at the time of injection upon statistical comparison of the results. No animal shall show any abnormal sign during the observation period.
Test for mouse leucocyte-increasing toxicity
The test sample shall be injected intraperitoneally at a dose of 0.5 ml into at least five mice of about 4 weeks of age. The mean count of leucocyte in peripheral blood 3 days after injection shall not exceed 10 times that before injection.
3.3.10
Potency test
The potency shall be determined in mice by the intracerebral challenge method. The test sample and Standard shall be so diluted as to make at least three levels of four-fold or other suitable logarithmic serial dilutions, respectively.
Each dilution shall be injected intraperitoneally at a dose of 0.5 ml into at least 16 mice of about 4 weeks of age. The animals shall be of the same sex or both sexes in the equal numbers. On 10 days after immunizing injection, the challenge suspension shall be injected intracerebrally into the animals at a dose of 0.025 ml. The animals shall be observed for 14 days. Any animal dying within 3 days after challenge shall be excluded from the test. Any animal showing paralysis or swelling of the head at the end of the observation period shall be included in deaths.
Each of at least three appropriate serial dilutions of the challenge suspension shall be injected into at least 10 mice of about 5 weeks of age to titrate the virulence. The LD50 per 0.025 ml of the challenge suspension shall be 50-400. The viable count in the challenge suspension obtained by culturing on blood agar medium shall be about one fourth of the total bacteria count obtained by the opacity. 3.3.10.3 Criterion for judgment
The potency of the test sample shall be no less than that of the Standard upon statistical comparison of the results.
Identity test
The test shall be conducted by agglutination in tubes with immune serum against B. pertussis.
Storage and dating period
The dating period shall be 18 months.
5 Other requirements 5.1 Information to be given in the affixed leaflet 1) Name of strains used for production 2) The method used for inactivation of bacteria 3) Caution to make homogeneous by thorough shaking before use 4) Following recommended human dose and route of administration: For primary immunization, usually three doses of 0.5 ml are injected subcutaneously at intervals of 3-8 weeks.
For booster immunization, usually 0.5 ml is injected subcutaneously after 12-18 months of the completion of primary immunization.
DIPHTHERIA-PERTUSSIS-TETANUS
COMBINED VACCINE For primary immunization, usually three doses of 0.5 ml are injected subcutaneously with intervals of 3-8 weeks.
